Valuation: Outlook Therapeutics, Inc.

Market Cap 156M 137M 129M 118M 220M 14.92B 222M 1.54B 598M 7.62B 585M 572M 24.5B P/E 2026 *
-1.1x
P/E 2027 * -2.95x
Enterprise Value 156M 137M 129M 118M 220M 14.92B 222M 1.54B 598M 7.62B 585M 572M 24.5B EV / Sales 2026 *
228x
EV / Sales 2027 * 3.53x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day-2.49%
1 week-2.01%
Current month+0.96%
1 month+2.60%
3 months-62.60%
6 months+204.52%
Current year-59.53%
1 week 0.64
Extreme 0.636
0.71
1 month 0.6
Extreme 0.6043
0.74
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
18
5 years 0.16
Extreme 0.1611
46.2
10 years 0.16
Extreme 0.1611
704
Manager TitleAgeSince
Chief Executive Officer 54 2025-06-30
Director of Finance/CFO 59 2026-08-31
Chief Tech/Sci/R&D Officer - 2023-01-18
Director TitleAgeSince
Director/Board Member 65 2015-12-10
Chairman 41 2025-01-30
Director/Board Member 50 2017-10-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Chief Financial Officer

500,000 0.3122%
8/14/26 Buy

Chief Executive Officer

202,020 0.0832%
8/14/26 Buy

Chief Executive Officer

303,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
-2.49%-2.01%-34.08%-85.47% 156M
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average -0.17%+1.92%+51.92%+116.26% 27.02B
Weighted average by Cap. +0.11%+2.86%+79.60%+160.12%

Financials

2026 *2027 *
Net sales 683K 599K 566K 516K 965K 65.43M 972K 6.77M 2.62M 33.43M 2.56M 2.51M 107M 44.07M 38.67M 36.52M 33.28M 62.31M 4.22B 62.75M 437M 169M 2.16B 165M 162M 6.94B
Net income -65.1M -57.13M -53.95M -49.17M -92.04M -6.24B -92.7M -646M -250M -3.19B -244M -239M -10.24B -44.43M -38.99M -36.82M -33.56M -62.82M -4.26B -63.27M -441M -171M -2.18B -167M -163M -6.99B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26-09-25 $0.6395 -2.49% 2,936,198
26-09-24 $0.6558 -0.89% 2,780,153
26-09-23 $0.6617 -4.96% 2,932,303
26-09-22 $0.6962 +1.44% 2,864,500
26-09-21 $0.6863 +5.16% 2,877,699
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.6395USD
Average target price
5.025USD
Spread / Average Target
+685.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock